Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4+ T cells
被引:22
作者:
Beliakova-Bethell, Nadejda
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USAUniv Calif San Diego, Dept Med, La Jolla, CA 92093 USA
Beliakova-Bethell, Nadejda
[1
]
Zhang, Jin X.
论文数: 0引用数: 0
h-index: 0
机构:
Vet Affairs San Diego Healthcare Syst, San Diego, CA USAUniv Calif San Diego, Dept Med, La Jolla, CA 92093 USA
Zhang, Jin X.
[2
]
Singhania, Akul
论文数: 0引用数: 0
h-index: 0
机构:
Vet Affairs San Diego Healthcare Syst, San Diego, CA USAUniv Calif San Diego, Dept Med, La Jolla, CA 92093 USA
Singhania, Akul
[2
]
Lee, Vivian
论文数: 0引用数: 0
h-index: 0
机构:
Vet Affairs San Diego Healthcare Syst, San Diego, CA USAUniv Calif San Diego, Dept Med, La Jolla, CA 92093 USA
Lee, Vivian
[2
]
Terry, Valeri H.
论文数: 0引用数: 0
h-index: 0
机构:
Vet Affairs San Diego Healthcare Syst, San Diego, CA USAUniv Calif San Diego, Dept Med, La Jolla, CA 92093 USA
Terry, Valeri H.
[2
]
Richman, Douglas D.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
Vet Affairs San Diego Healthcare Syst, San Diego, CA USA
Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USAUniv Calif San Diego, Dept Med, La Jolla, CA 92093 USA
Richman, Douglas D.
[1
,2
,3
]
Spina, Celsa A.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USAUniv Calif San Diego, Dept Med, La Jolla, CA 92093 USA
Spina, Celsa A.
[1
,3
]
Woelk, Christopher H.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
Vet Affairs San Diego Healthcare Syst, San Diego, CA USAUniv Calif San Diego, Dept Med, La Jolla, CA 92093 USA
Woelk, Christopher H.
[1
,2
]
机构:
[1] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
[2] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA
[3] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA
Objective: To assess the off-target effects of the histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA) in human primary CD4(+) T cells. Design: A pharmacologically relevant concentration (340 nmol/l) of SAHA was shown to significantly increase histone hyperacetylation by 24 h and this length of treatment was selected to determine its impact on gene expression in primary CD4(+) T cells. Methods: Illumina Beadchips for microarray gene expression analysis were used to analyze differential gene expression between cells treated or not with SAHA with a paired analysis using multivariate permutation tests. Gene ontology, biological pathway and protein interaction network analyses were used to identify the higher order biological processes affected by SAHA treatment. Results: Modest modulation by SAHA was observed for 1847 genes with 80% confidence level of no more than 10% false positives. A thousand genes were upregulated by SAHA and 847 downregulated. Pathways and gene ontologies overrepresented in the list of differentially expressed genes included Glycolysis/Gluconeogenesis, tRNA Modification, and the Histone Acetyltransferase Complex. Protein interaction network analysis revealed that transcription factor c-Myc, which was downregulated by SAHA treatment at the mRNA level, interacts with a number of SAHA-responsive genes. Conclusions: The effects on transcription by SAHA were sufficiently modest to support trials to activate HIV replication as part of an eradication strategy. SAHA did not appear to modulate proliferative or apoptotic processes to a great extent, which might impact the ability of patients to eradicate the virus reservoir following activation by HDACi treatment. (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins AIDS 2013, 27:29-37
机构:
US FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USAUS FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USA
Mann, Bhupinder S.
Johnson, John R.
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USAUS FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USA
Johnson, John R.
Cohen, Martin H.
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USAUS FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USA
Cohen, Martin H.
Justice, Robert
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USAUS FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USA
Justice, Robert
Pazdur, Richard
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USAUS FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USA
机构:
US FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USAUS FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USA
Mann, Bhupinder S.
Johnson, John R.
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USAUS FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USA
Johnson, John R.
Cohen, Martin H.
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USAUS FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USA
Cohen, Martin H.
Justice, Robert
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USAUS FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USA
Justice, Robert
Pazdur, Richard
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USAUS FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USA